In this study, we aimed to determine (1) whether assessments of TIMP-1 gene copy number in the tumor cells and/or (2) measurement of plasma TIMP-1 protein levels could substitute TIMP-1 immunohistochemistry in glioma research. This evidence concerns the gene TIMP1 and central nervous system cancer.